DDInter112 DDInter1658
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Aprepitant {u} (Compound) resembles {v} (Compound) Fosaprepitant
Aprepitant {u} (Compound) binds {v} (Gene) CYP1A2
Aprepitant {u} (Compound) palliates {v} (Disease) colon cancer
Aprepitant {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Aprepitant {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Aprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Aprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Citalopram
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Toremifene
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Aprepitant {u} may lead to a major life threatening interaction when taken with {v} Deflazacort
Aprepitant (Compound) resembles Fosaprepitant (Compound)
Aprepitant (Compound) binds CYP1A2 (Gene)
Aprepitant (Compound) palliates colon cancer (Disease)
Aprepitant (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class)
Aprepitant (Compound) causes Myocardial infarction (Side Effect)
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Citalopram
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Toremifene
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Aprepitant may lead to a major life threatening interaction when taken with Deflazacort